Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 71Neoplasms 64Prostatic Neoplasms 45Colorectal Neoplasms 41Lung Neoplasms 37Carcinoma, Non-Small-Cell Lung 26Pancreatic Neoplasms 21Neoplasm Metastasis 20Hematologic Neoplasms 20Head and Neck Neoplasms 19Urinary Bladder Neoplasms 15Ovarian Neoplasms 14Multiple Myeloma 11Motor Activity 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Glioblastoma 9Colonic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Gastrointestinal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8Rectal Neoplasms 7Melanoma 7

Interventions

Epoetin Alfa 53Darbepoetin alfa 38epoetin beta 12ferric carboxymaltose 11Lenalidomide 5Cyclophosphamide 5luspatercept 4fludarabine phosphate 4fludarabine 4Erythropoietin 4Cyclosporine 4Cisplatin 4Busulfan 4Blood Transfusion 4ACE-011 4peginesatide 3iron isomaltoside 1000 3hematide 3ferrous sulfate 3ferric gluconate 3Radiotherapy 3Iron-Dextran Complex 3Filgrastim 3Ferric Oxide, Saccharated 3Biopsy 3Antilymphocyte Serum 3thymoglobulin 2telapristone acetate 2ruxolitinib 2ferrous fumarate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anemia × Standard of Care × Clear all
NCT00224068 2012-03-02

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Watson Pharmaceuticals

Phase 4 Completed
180 enrolled
Classical hematology

Iron Deficiencies, Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡